Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.
Sector:
Health Technology
Industry:
Pharmaceuticals Generic
Employees:
83
Frequently Asked Questions
What is Market Cap of Aratana Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aratana Therapeutics Inc market cap is N/A.
What is the 52-week high for Aratana Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aratana Therapeutics Inc 52 week high is $7.16 as of September 10, 2025.
What is the 52-week low for Aratana Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aratana Therapeutics Inc 52 week low is $3.30 as of September 10, 2025.
What was Aratana Therapeutics Inc stock price yesterday?
Aratana Therapeutics Inc stock price yesterday was $4.92.
What is the PE ratio of Aratana Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Aratana Therapeutics Inc’s P/E ratio is None.
What is the Price-to-Book ratio of Aratana Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aratana Therapeutics Inc P/B ratio is None.
What is Aratana Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Aratana Therapeutics Inc's EBITDA is -13.73.
What is the 50-day moving average of Aratana Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aratana Therapeutics Inc 50-day moving average is $4.97.
How many employess does Aratana Therapeutics Inc has?